Canton Hathaway’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $83.3K | Sell |
1,445
-1,950
| -57% | -$112K | 0.02% | 168 |
|
|
2026
Q1 | $206K | Buy |
3,395
+125
| +4% | +$7.29K | 0.04% | 128 |
|
|
2025
Q4 | $176K | Buy |
3,270
+1,950
| +148% | +$93.8K | 0.03% | 139 |
|
|
2025
Q3 | $60K | Hold |
1,320
| – | – | 0.01% | 195 |
|
|
2025
Q2 | $61K | Buy |
1,320
+50
| +4% | +$2.45K | 0.01% | 186 |
|
|
2025
Q1 | $77K | Buy |
1,270
+275
| +28% | +$16K | 0.02% | 175 |
|
|
2024
Q4 | $56K | Buy |
995
+300
| +43% | +$16.8K | 0.01% | 155 |
|
|
2024
Q3 | $36K | Hold |
695
| – | – | 0.01% | 187 |
|
|
2024
Q2 | $29K | Hold |
695
| – | – | 0.01% | 202 |
|
|
2024
Q1 | $38K | Hold |
695
| – | – | 0.01% | 176 |
|
|
2023
Q4 | $36K | Hold |
695
| – | – | 0.01% | 181 |
|
|
2023
Q3 | $40K | Hold |
695
| – | – | 0.01% | 167 |
|
|
2023
Q2 | $44K | Hold |
695
| – | – | 0.01% | 166 |
|
|
2023
Q1 | $48K | Hold |
695
| – | – | 0.02% | 157 |
|
|
2022
Q4 | $50K | Hold |
695
| – | – | 0.02% | 162 |
|
|
2022
Q3 | $49K | Sell |
695
-500
| -42% | -$36.3K | 0.02% | 153 |
|
|
2022
Q2 | $92K | Hold |
1,195
| – | – | 0.03% | 127 |
|
|
2022
Q1 | $87K | Hold |
1,195
| – | – | 0.02% | 136 |
|
|
2021
Q4 | $75K | Sell |
1,195
-25,343
| -95% | -$1.49M | 0.02% | 157 |
|
|
2021
Q3 | $1.57M | Sell |
26,538
-4,505
| -15% | -$297K | 0.45% | 43 |
|
|
2021
Q2 | $2.07M | Sell |
31,043
-839
| -3% | -$54.7K | 0.61% | 33 |
|
|
2021
Q1 | $2.01M | Buy |
31,882
+6,582
| +26% | +$410K | 0.64% | 29 |
|
|
2020
Q4 | $1.57M | Buy |
25,300
+9,110
| +56% | +$560K | 0.53% | 37 |
|
|
2020
Q3 | $976K | Buy |
16,190
+10,290
| +174% | +$619K | 0.4% | 36 |
|
|
2020
Q2 | $347K | Sell |
5,900
-940
| -14% | -$56.2K | 0.23% | 52 |
|
|
2020
Q1 | $381K | Buy |
6,840
+940
| +16% | +$57.5K | 0.27% | 40 |
|
|
2019
Q4 | $379K | Sell |
5,900
-870
| -13% | -$49.8K | 0.19% | 61 |
|
|
2019
Q3 | $343K | Buy |
6,770
+6,270
| +1,254% | +$295K | 0.19% | 61 |
|
|
2019
Q2 | $23K | Hold |
500
| – | – | 0.01% | 171 |
|
|
2019
Q1 | $23K | Hold |
500
| – | – | 0.01% | 170 |
|
|
2018
Q4 | $26K | Hold |
500
| – | – | 0.02% | 130 |
|
|
2018
Q3 | $31K | Buy |
+500
| New | +$29.7K | 0.02% | 117 |
|
Other funds holding BMY
Canton Hathaway's BMY Position: Q2 2026 in Review
Canton Hathaway reduced its Bristol-Myers Squibb (BMY) stake by 57% in Q2 2026, selling an estimated $112K and leaving 1,445 shares worth $83.3K. The position accounts for 0.02% of the portfolio, ranked #168.
Canton Hathaway first reported a position in BMY in Q3 2018 and has held it in 32 quarters since. The position peaked at $2.07M in Q2 2021. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Canton Hathaway held 1,445 shares of Bristol-Myers Squibb worth $83.3K as of Q2 2026.
- Canton Hathaway sold 1,950 Bristol-Myers Squibb shares in Q2 2026, an estimated $112K.
- Bristol-Myers Squibb made up 0.02% of Canton Hathaway's portfolio in Q2 2026, its #168 holding.
- Canton Hathaway first reported a position in Bristol-Myers Squibb in Q3 2018 and has held it in 32 quarters since.
- Canton Hathaway's Bristol-Myers Squibb position peaked at $2.07M in Q2 2021.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Canton Hathaway's 13F filing for Q2 2026, filed 6 Aug 2026.